Status:
ACTIVE_NOT_RECRUITING
Cisgender Female Patients Who Start on Long Acting Cabotegravir for PrEP
Lead Sponsor:
Midway Specialty Care Center
Conditions:
Hiv
Eligibility:
FEMALE
18+ years
Brief Summary
Oral PrEP regimens (FTC/TDF have been the mainstay of HIV prevention however patients now have more options for HIV prevention. In addition to oral PrEP regimens, the FDA approved the use of long acti...
Eligibility Criteria
Inclusion
- Cisgender females, ages 18 years and older
- Negative HIV test at baseline
- Negative Pregnancy test at baseline
- Weigh at least 35 kilograms
- Already Prescribed CAB-LA (Apretude)
Exclusion
- Transgender females or males
- Cisgender males
- Cisgender female who is actively breastfeeding
- Severe hepatotoxicity
- Evidence of Hepatitis B Infection
- History or presence of allergies to cabotegravir or its components
Key Trial Info
Start Date :
January 2 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 31 2027
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06145854
Start Date
January 2 2024
End Date
March 31 2027
Last Update
November 3 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Midway Specialty Care Center
Orlando, Florida, United States, 32819
2
Midway Specialty Care Center
Temple Terrace, Florida, United States, 33617
3
Midway Specialty Care Center
West Palm Beach, Florida, United States, 33401